Journal of pharmacy & bioallied sciences · 2025
Role of Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Clinical Diagnosed Alzheimer's Diseases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Timalsina Dilip Raj, Abichandani Leela, Ambad Ranjit
Аннотация
INTRODUCTION: Alzheimer's disease (AD), a neurodegenerative disorder closely associated with aging, is characterized by progressive cognitive decline and is a leading cause of dementia worldwide. Oxidative stress plays a pivotal role in AD's pathophysiology, contributing to amyloid-beta accumulation, neurofibrillary tangles, and neuronal damage.
AIM: This study investigates the potential of F2-isoprostanes and Presenilin-1 (PSEN1) as biomarkers for oxidative stress and their association with clinically diagnosed Alzheimer's disease.
MATERIALS AND METHODS: A comparative cross-sectional study will be conducted, enrolling 50 AD patients and 50 age-matched healthy controls from the Vidarbha region. Serum levels of F2-isoprostanes and PSEN1 will be measured using advanced analytical techniques, and their correlation with AD progression will be analyzed statistically.
RESULTS AND CONCLUSION: The findings are expected to provide insights into the diagnostic and prognostic value of these markers, offering potential avenues for early detection and therapeutic intervention in Alzheimer's disease.
AIM: This study investigates the potential of F2-isoprostanes and Presenilin-1 (PSEN1) as biomarkers for oxidative stress and their association with clinically diagnosed Alzheimer's disease.
MATERIALS AND METHODS: A comparative cross-sectional study will be conducted, enrolling 50 AD patients and 50 age-matched healthy controls from the Vidarbha region. Serum levels of F2-isoprostanes and PSEN1 will be measured using advanced analytical techniques, and their correlation with AD progression will be analyzed statistically.
RESULTS AND CONCLUSION: The findings are expected to provide insights into the diagnostic and prognostic value of these markers, offering potential avenues for early detection and therapeutic intervention in Alzheimer's disease.